These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 22672003)

  • 21. Ranibizumab versus bevacizumab for the treatment of neovascular age-related macular degeneration.
    Abouammoh M; Sharma S
    Curr Opin Ophthalmol; 2011 May; 22(3):152-8. PubMed ID: 21483262
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cheap shots and pricey propositions: evidence, disclosure, and treatment of age-related macular degeneration.
    Kimmelman J
    Retina; 2007; 27(9):1166-7. PubMed ID: 18046219
    [No Abstract]   [Full Text] [Related]  

  • 23. Tachyphylaxis and bevacizumab.
    Avgikos KN; Horgan SE; Sivaraj RR; Hu K
    Ophthalmology; 2009 Sep; 116(9):1831-2; author reply 1832. PubMed ID: 19729101
    [No Abstract]   [Full Text] [Related]  

  • 24. Tachyphylaxis and bevacizumab.
    Ziemssen F; Neuhann IM; Voelker M
    Ophthalmology; 2009 Aug; 116(8):1591-2; author reply 1592-3. PubMed ID: 19651319
    [No Abstract]   [Full Text] [Related]  

  • 25. Bevacizumab and ranibizumab. Bevacizumab and the inverse postcode lottery.
    Harris MJ
    BMJ; 2010 Jul; 341():c3718. PubMed ID: 20627986
    [No Abstract]   [Full Text] [Related]  

  • 26. What is stopping the NHS from using bevacizumab for macular degeneration and other retinal disorders?
    Lotery A; MacEwen C
    BMJ; 2014 Nov; 349():g6887. PubMed ID: 25406142
    [No Abstract]   [Full Text] [Related]  

  • 27. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
    Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
    J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pharmacokinetic rationale for dosing every 2 weeks versus 4 weeks with intravitreal ranibizumab, bevacizumab, and aflibercept (vascular endothelial growth factor Trap-eye).
    Stewart MW; Rosenfeld PJ; Penha FM; Wang F; Yehoshua Z; Bueno-Lopez E; Lopez PF
    Retina; 2012 Mar; 32(3):434-57. PubMed ID: 22374154
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bevacizumab tachyphylaxis.
    Falavarjani KG; Modarres M
    Ophthalmology; 2009 May; 116(5):1016-7; author reply 1017. PubMed ID: 19410964
    [No Abstract]   [Full Text] [Related]  

  • 30. Duration of action of intravitreal ranibizumab and bevacizumab in exudative AMD eyes based on macular volume measurements.
    Shah AR; Del Priore LV
    Br J Ophthalmol; 2009 Aug; 93(8):1027-32. PubMed ID: 19429594
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bevacizumab: not as good with more adverse reactions?
    Beaumont P
    Clin Exp Ophthalmol; 2011 Aug; 39(6):588-90. PubMed ID: 21631687
    [No Abstract]   [Full Text] [Related]  

  • 32. Bevacizumab versus ranibizumab: why are we not playing the joker?
    Banfi R; Attanasio F; Palazzi N; Colombini S; Falai T; Cecchi M; Virgili G
    Int J Clin Pharm; 2013 Aug; 35(4):507-9. PubMed ID: 23625322
    [No Abstract]   [Full Text] [Related]  

  • 33. Ophthalmic Statistics Note 4: analysing data from randomised controlled trials with baseline and follow-up measurements.
    Nash R; Bunce C; Freemantle N; Doré CJ; Rogers CA;
    Br J Ophthalmol; 2014 Nov; 98(11):1467-9. PubMed ID: 25107901
    [No Abstract]   [Full Text] [Related]  

  • 34. [A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
    Holz FG
    MMW Fortschr Med; 2007 Jan; 149(3):13-4. PubMed ID: 17619376
    [No Abstract]   [Full Text] [Related]  

  • 35. Treatments for macular degeneration: summarising evidence using network meta-analysis.
    Fadda V; Maratea D; Trippoli S; Messori A
    Br J Ophthalmol; 2011 Oct; 95(10):1476-7. PubMed ID: 21680571
    [No Abstract]   [Full Text] [Related]  

  • 36. Anti vascular endothelial growth factor sequential therapy for neovascular age-related macular degeneration: is this the new deal?
    Neri P; Mariotti C; Arapi I; Bambini E; Giovannini A
    Curr Med Res Opin; 2012 Mar; 28(3):395-400. PubMed ID: 22283373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Bevacizumab versus ranibizumab: a draw?].
    Souied EH; Cohen SY; Kodjikian L
    J Fr Ophtalmol; 2012 Feb; 35(2):79-81. PubMed ID: 22033297
    [No Abstract]   [Full Text] [Related]  

  • 38. Shifting exudative age-related macular degeneration patients to ranibizumab after insufficient response to bevacizumab.
    de Geus SJ; Jager MJ; Luyten GP; Dijkman G
    Acta Ophthalmol; 2013 Aug; 91(5):e411-3. PubMed ID: 23551594
    [No Abstract]   [Full Text] [Related]  

  • 39. Bevacizumab: a new way of doing business?
    Canning C; Lotery A
    Eye (Lond); 2006 Sep; 20(9):985-7. PubMed ID: 16858443
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Long term effects of anti-VEGF agents: patho-physiological perspectives.
    Gupta M; Gupta Y; Phougat A
    Nepal J Ophthalmol; 2013; 5(1):100-5. PubMed ID: 23584654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.